Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2026 23:39 ET | Source: Direct Meds

Direct Meds GLP-1 2026: Claims Examined, Pricing Verified & What Consumers Should Confirm Before Buying

New York City, NY, April 18, 2026 (GLOBE NEWSWIRE) -- You've done the diets. Probably more than once. You've tracked calories, cut carbs, tried intermittent fasting, started gym memberships in...
March 09, 2026 18:10 ET | Source: Direct Meds

Direct Meds GLP-1 Program Report 2026: Compounded Semaglutide and Tirzepatide Pricing, Telehealth Access, and Consumer Verification Factors

2026 report on Direct Meds' compounded semaglutide and tirzepatide GLP-1 program, including pricing, telehealth process, and delivery formats.
January 10, 2026 18:12 ET | Source: Direct Meds

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

Direct Meds reviews best GLP-1 weight loss shot prescription pathways for 2026 as oral semaglutide and injectable formats expand patient access.
January 07, 2026 20:05 ET | Source: Direct Meds

Best Oral Peptides for Weight Loss: Injectable vs Sublingual vs Daily Pill – Direct Meds Consumer Analysis

January 2026 consumer analysis compares oral Wegovy, compounded sublingual semaglutide, and tirzepatide drops across pricing and access formats.
January 06, 2026 21:10 ET | Source: Direct Meds

Best Peptides for Weight Loss 2026: Oral Wegovy Launch Expands GLP-1 Format Options as Telehealth Platforms Compare FDA-Approved vs Compounded Semaglutide Access

Oral Wegovy launch expands GLP-1 format options as Direct Meds telehealth platform compares FDA-approved vs compounded semaglutide pricing structures.
December 30, 2025 20:57 ET | Source: Direct Meds

Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study

Industry analysis examines how patients verify telehealth GLP-1 platforms after FDA oral semaglutide approval. Direct Meds included as case study.
December 26, 2025 23:34 ET | Source: Direct Meds

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Analysis examines Direct Meds GLP-1 medications platform as LegitScript-certified telehealth option for compounded semaglutide and tirzepatide access.